Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.

IMAC Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE FIRST PRECISION ONCOLOGY TRIAL TO USE A FUNCTIONAL PROTEOMICS AND PHOSPHOPROTEOMICS ASSAY FOR TREATMENT DECISION MAKING IN A PAN-TUMOR STUDY

IGNITE PROTEOMICS ANNOUNCES COLLABORATION WITH INOVA HEALTH ON A BIOMARKER STUDY FOR LATE-STAGE CANCERS

GOLDEN, CO, FEB. 24, 2025 (GLOBE NEWSWIRE) -- IGNITE PROTEOMICS LLC, A SUBSIDIARY OF IMAC HOLDINGS, INC. (NASDAQ: BACK), TODAY ANNOUNCED THE PRESENTATION OF NEW DATA DEMONSTRATING THAT MHC-II PROTEIN EXPRESSION IS A SUPERIOR PREDICTOR OF RESPONSE TO PEMBROLIZUMAB (KEYTRUDA) COMPARED TO PD-L1 AT THE UPCOMING NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) ANNUAL CONFERENCE. THE STUDY, CONDUCTED WITH I-SPY 2 CLINICAL TRIAL RESULTS, EVALUATED FIVE DIFFERENT PD-L1 ANTIBODIES  INCLUDING THE ONE MOST COMMONLY USED AS A COMPANION DIAGNOSTIC  YET ONLY MHC-II EXPRESSION SHOWED A STATISTICALLY SIGNIFICANT CORRELATION WITH PATIENT OUTCOMES.

IGNITE PROTEOMICS TO PRESENT DATA ON MHC-II AS A PREDICTOR OF PEMBROLIZUMAB RESPONSE AT NCCN ANNUAL CONFERENCE

GOLDEN, CO, FEB. 19, 2025 (GLOBE NEWSWIRE) -- IGNITE PROTEOMICS LLC, A SUBSIDIARY OF IMAC HOLDINGS, INC. (NASDAQ: BACK), TODAY ANNOUNCED THE COMPLETED TRANSFER OF PROPRIETARY LABORATORY ANALYSES (PLA) CODE 0249U  ORIGINALLY ISSUED TO THERALINK TECHNOLOGIES, INC.  TO IGNITE PROTEOMICS LLC. THE AMA CPT CODE IS LISTED ON THE MEDICARE CLINICAL LABORATORY FEE SCHEDULE (CLFS) AND IS ADDRESSED BY THE PALMETTO GBA MOLDX PROTEOMICS TESTING ARTICLE (A59636). THIS MILESTONE INTEGRATES BOTH THE LABORATORY CAPABILITY AND THE OWNED AND LICENSED INTELLECTUAL PROPERTY OF THE PROTEOMIC BREAST CANCER ASSAY INTO IGNITE PROTEOMICS.

IGNITE PROTEOMICS COMPLETES ACQUISITION OF PLA CODE 0249U FOR ITS ADVANCED PROTEOMIC BREAST CANCER ASSAY

THE NEW STUDY ADDS TO GROWING EVIDENCE THAT MEASURING ACTIVATED PROTEINS IS KEY TO CANCER THERAPY SELECTION. GOLDEN, CO, FEB. 10, 2025 (GLOBE NEWSWIRE) -- IGNITE PROTEOMICS LLC, A SUBSIDIARY OF IMAC HOLDINGS, INC. (NASDAQ: BACK), ANNOUNCES THE PUBLICATION OF A SIGNIFICANT STUDY IN THEBRITISH JOURNAL OF CANCER TITLED "FUNCTIONAL ACTIVATION OF THE AKTMTOR SIGNALLING AXIS IN A REAL-WORLD METASTATIC BREAST CANCER COHORT".

IGNITE PROTEOMICS ANNOUNCES PUBLICATION OF STUDY DEMONSTRATING SUPERIORITY OF PROTEIN ACTIVATION ANALYSIS IN PREDICTING BREAST CANCER THERAPY RESPONSE

NASHVILLE, TN, JAN. 27, 2025 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (NASDAQ: BACK) (IMAC HOLDINGS OR THE COMPANY) HAS LAUNCHED IGNITE PROTEOMICS LLC (IGNITE), ITS NEW SUBSIDIARY DEDICATED TO HELPING DOCTORS SELECT THE MOST EFFECTIVE CANCER TREATMENTS BASED ON PROTEIN-LEVEL INSIGHTS. THIS MOVE ADDRESSES A GROWING NEED FOR BETTER, FASTER WAYS TO PERSONALIZE THERAPY IN BREAST CANCER AND BEYOND.

IMAC HOLDINGS INTRODUCES IGNITE PROTEOMICS: A NEW STANDARD FOR MATCHING PATIENTS WITH THE RIGHT CANCER THERAPIES

FRANKLIN, TN, NOV. 22, 2024 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (IMAC OR THE COMPANY) (NASDAQ: BACK) TODAY ANNOUNCED THAT IT RECEIVED AN EXPECTED DEFICIENCY NOTIFICATION LETTER FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC (NASDAQ) ON NOVEMBER 22, 2024 (THE NOTICE). THE NOTICE INDICATED THAT THE COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1) (THE LISTING RULE) AS A RESULT OF ITS FAILURE TO TIMELY FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2024 (THE FORM 10-Q), AS DESCRIBED MORE FULLY IN THE COMPANY'S FORM 12B-25 NOTIFICATION OF LATE FILING (THE FORM 12B-25) FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE SEC) ON NOVEMBER 15, 2024. THE LISTING RULE REQUIRES NASDAQ-LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THE SEC.

IMAC HOLDINGS RECEIVES NOTIFICATION OF DEFICIENCY FROM NASDAQ RELATED TO DELAYED FILING OF QUARTERLY REPORT ON FORM 10-Q

FRANKLIN, TN, NOV. 14, 2024 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (IMAC OR THE COMPANY) (NASDAQ: BACK) TODAY ANNOUNCED THAT IT HAS RECEIVED AN EXCEPTION FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC (NASDAQ) TO REGAIN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1) (THE LISTING RULE). THIS EXCEPTION EXTENDS THE DEADLINE FOR THE COMPANY TO FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2024 (THE FORM 10-Q) UNTIL FEBRUARY 17, 2025.

IMAC HOLDINGS GRANTED EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH LISTING RULE 5250(C)(1)

NASHVILLE, TN, SEPT. 19, 2024 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (NASDAQ: BACK) (IMAC HOLDINGS OR THE COMPANY), A LEADER IN INNOVATIVE HEALTHCARE SOLUTIONS, PROUDLY ANNOUNCES THE LAUNCH OF AN ENTIRELY NEW PRECISION ONCOLOGY ASSAY FOR BREAST CANCER TREATMENT DECISION MAKING UTILIZING THE REVERSE PHASE PROTEIN ARRAY (RPPA) TECHNOLOGY THROUGH ITS NEWLY ESTABLISHED SUBSIDIARY, IGNITE PROTEOMICS LLC (IGNITE PROTEOMICS). THIS LAUNCH FOLLOWS IMAC HOLDINGS' STRATEGIC ACQUISITION OF KEY ASSETS FROM THERALINK TECHNOLOGIES, INC., AND IS UNDERSCORED BY A LANDMARK CLINICAL CASE STUDY  PROTEOMICS BASED SELECTION ACHIEVES COMPLETE RESPONSE TO HER2 THERAPY IN HER2 IHC 0 BREAST CANCER, DEMONSTRATING THE POWER OF RPPA TECHNOLOGY IN PRECISION ONCOLOGY PUBLISHED IN NPJ PRECISION ONCOLOGY, AN INTERNATIONAL, PEER-REVIEWED JOURNAL FOCUSED ON PRECISION ONCOLOGY.

IMAC HOLDINGS INC. LAUNCHES SUBSIDIARY IGNITE PROTEOMICS AND ANNOUNCES GROUNDBREAKING PRECISION ONCOLOGY CASE STUDY UTILIZING RPPA TECHNOLOGY

FRANKLIN, TN, AUG. 23, 2024 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (IMAC OR THE COMPANY) (NASDAQ: BACK) TODAY ANNOUNCED THAT IT RECEIVED AN EXPECTED DEFICIENCY NOTIFICATION LETTER FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC (NASDAQ) ON AUGUST 21, 2024 (THE NOTICE). THE NOTICE INDICATED THAT THE COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1) (THE LISTING RULE) AS A RESULT OF ITS FAILURE TO TIMELY FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2024 (THE FORM 10-Q), AS DESCRIBED MORE FULLY IN THE COMPANY'S FORM 12B-25 NOTIFICATION OF LATE FILING (THE FORM 12B-25) FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE SEC) ON AUGUST 15, 2024. THE LISTING RULE REQUIRES NASDAQ-LISTED COMPANIES TO TIMELY FILE ALL REQUIRED PERIODIC REPORTS WITH THE SEC.

GOLDEN, CO, JULY 11, 2024 (GLOBE NEWSWIRE) -- IMAC HOLDINGS, INC. (NASDAQ: BACK) (THE COMPANY OR IMAC), A LEADING INNOVATOR IN PROTEOMICS RESEARCH AND TECHNOLOGY, ANNOUNCED THE APPOINTMENT OF DR. PETER BEITSCH AND DR. MATTHEW SCHWARTZ TO ITS BOARD OF DIRECTORS, EFFECTIVE JUNE 26, 2024. THIS STRATEGIC MOVE UNDERSCORES THE COMPANY'S COMMITMENT TO ADVANCING ITS POSITION IN THE FIELD OF PROTEOMICS AND DRIVING INNOVATION IN PRECISION MEDICINE.

IMAC Holdings, Inc.

BACK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMAC Holdings, Inc.

BACK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BACK